In 2023, the import of insulin in dosage forms to China stood at an actual value below the 2024 forecast of $842.87 million. The forecast shows a steady increase in import value, with projections of $863.92 million in 2025 and $924.57 million by 2028. This consistent upward trend suggests a year-on-year growth due to rising demand driven by factors such as increasing diabetes prevalence in China. Over the next five years, the compound annual growth rate (CAGR) is modest, indicating stable, gradually increasing import levels.
Future trends to watch for include advancements in domestic insulin production, changes in health policy and regulation, and innovations in diabetes treatment that could impact import reliance. Additionally, China's pharmaceutical market reforms and potential international trade agreements could influence import patterns significantly.
